Health Care • Medical/Dental Instruments
$0.92 ▼ -0.06
(-5.74%)
MKT CAP: $41.5M • VOL: 49.3K
52W L $1 52W H $2
ROARABLE / RQD
D- • 36/100
PIOTROSKI
4 / 9
TELA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $80.3M | $69.3M | $58.5M |
| YoY Revenue Growth % | +15.8% | +18.6% | — |
| Gross Profit | $54.3M | $46.5M | — |
| Gross Margin % | 67.7% | 67.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$33.8M | -$34.1M | -$44.1M |
| Operating Margin % | -42.0% | -49.2% | -75.4% |
| Net Income (GAAP) | -$38.8M | -$37.8M | -$46.7M |
| EBITDA (Normalized) | -$33.4M | -$33.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$28.2M | -$41.6M | -$40.9M |
| Capital Expenditures (CapEx) | $448.0K | $989.0K | — |
| Free Cash Flow (FCF) | -$28.7M | -$42.6M | -$40.9M |
| FCF Margin % | -35.7% | -61.4% | -69.9% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $50.8M | $52.7M | — |
| Total Debt (Short + Long Term) | $55.7M | $41.1M | — |
| Total Stockholders' Equity | $6.3M | $28.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TELA.